Refractory status epilepticus
Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks
Marinus Pharmaceuticals, layoffs, workforce reduction, clinical setbacks, ganaxolone, seizures, tuberous sclerosis complex (TSC), refractory status epilepticus (RSE)
Marinus Pharmaceuticals Slashes 45% of Workforce Following Disappointing Phase 3 Trial Results
Marinus Pharmaceuticals, staff layoffs, phase 3 trials, ganaxolone, refractory status epilepticus, RAISE trial, TrustTSC trial